Recently, hepatic AQP9 was found downregulated in obese patients with NAFLD and steatohepatitis (NASH), with even lower levels in patients with insulin-resistance, suggesting a compensatory mechanism to prevent glycerol availability for triglycerides accumulation and hepatic gluconeogenesis (Rodriguez et al., 2014). Here, AQP9 is linked to Insulin resistance.